Depicting changes in tumor biology in response to cetuximab monotherapy or combination therapy by apoptosis and proliferation imaging using 18F-ICMT-11 and …
K Heinzmann, QD Nguyen, D Honess… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Imaging biomarkers must demonstrate their value in monitoring treatment. Two PET tracers,
the caspase-3/7–specific isatin-5-sulfonamide 18F-ICMT-11 (18F-(S)-1-((1-(2-fluoroethyl) …
the caspase-3/7–specific isatin-5-sulfonamide 18F-ICMT-11 (18F-(S)-1-((1-(2-fluoroethyl) …
18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts
S Takeuchi, S Zhao, Y Kuge, Y Zhao… - Oncology …, 2011 - spandidos-publications.com
We investigated whether 18F-fluorothymidine-positron-emission tomography/computed
tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti …
tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti …
18F-ICMT-11, a caspase-3–specific PET tracer for apoptosis: biodistribution and radiation dosimetry
A Challapalli, LM Kenny, WA Hallett… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Effective anticancer therapy induces tumor cell death through apoptosis. Noninvasive
monitoring of apoptosis during therapy may provide predictive outcome information and help …
monitoring of apoptosis during therapy may provide predictive outcome information and help …
111In-cetuximab-F (ab′) 2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in …
LK van Dijk, OC Boerman, GM Franssen… - Journal of Nuclear …, 2015 - Soc Nuclear Med
Treatment of head and neck squamous cell carcinomas with radiotherapy and the epidermal
growth factor receptor (EGFR) inhibitor cetuximab shows an improved response in a …
growth factor receptor (EGFR) inhibitor cetuximab shows an improved response in a …
Early response monitoring with 18F-FDG PET and cetuximab-F (ab′) 2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse …
LK van Dijk, OC Boerman, GM Franssen… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Only a subset of patients with head and neck squamous cell carcinomas (HNSCCs) benefit
from radiotherapy and concurrent epidermal growth factor receptor (EGFR) inhibitor therapy …
from radiotherapy and concurrent epidermal growth factor receptor (EGFR) inhibitor therapy …
[HTML][HTML] Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer
SR Dubash, S Merchant, K Heinzmann, F Mauri… - European journal of …, 2018 - Springer
Background Effective anticancer therapy is thought to involve induction of tumour cell death
through apoptosis and/or necrosis.[18 F] ICMT-11, an isatin sulfonamide caspase-3/7 …
through apoptosis and/or necrosis.[18 F] ICMT-11, an isatin sulfonamide caspase-3/7 …
PET of EGFR with 64Cu‐cetuximab‐F(ab′)2 in mice with head and neck squamous cell carcinoma xenografts
LK van Dijk, CB Yim, GM Franssen… - Contrast Media & …, 2016 - Wiley Online Library
Overexpression of the epidermal growth factor receptor (EGFR) is linked to an adverse
outcome in various solid tumors. Cetuximab is an EGFR inhibitor, which in combination with …
outcome in various solid tumors. Cetuximab is an EGFR inhibitor, which in combination with …
Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F (ab′) 2
LK van Dijk, BAW Hoeben… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Combined treatment of advanced head and neck squamous cell carcinomas (HNSCC) with
radiotherapy and the epidermal growth factor receptor (EGFR) inhibitor cetuximab improves …
radiotherapy and the epidermal growth factor receptor (EGFR) inhibitor cetuximab improves …
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab
TK Nayak, CAS Regino, KJ Wong, DE Milenic… - European journal of …, 2010 - Springer
Purpose Cetuximab is a recombinant, human/mouse chimeric IgG 1 monoclonal antibody
that binds to the epidermal growth factor receptor (EGFR/HER1). Cetuximab is approved for …
that binds to the epidermal growth factor receptor (EGFR/HER1). Cetuximab is approved for …
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
Purpose Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor
receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients …
receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients …
Related searches
- cetuximab monotherapy combination therapy
- tumor biology combination therapy
- tumor biology cetuximab monotherapy
- proliferation imaging combination therapy
- proliferation imaging cetuximab monotherapy
- tumor biology proliferation imaging
- radiation dosimetry pet tracer
- clinical translation lung cancer
- tumor response treatment with cetuximab
- dtpa cetuximab pet imaging
- pet for prediction response monitoring
- tumor response early predictor
- xenografts in mice pet imaging